All sponsors

Otsuka Pharmaceutical Co., Ltd. $4578.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-38
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO12%

Delay Index: of 8 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Otsuka Pharmaceutical Co., Ltd. on the live radar map → 📅 $4578.T readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
OPA-15406
NCT07173478
P3Not yet recruitingAtopic Dermatitis (AD)1562026-12
OPA-15406
NCT07184645
P3Not yet recruitingAtopic Dermatitis (AD)1982027-02
EB-1020 (Centanafadine) low dose
NCT07086313
P2/3RecruitingAttention-Deficit Hyperactivity Disorder(ADHD)3152027-08
EB-1020 (Centanafadine) low dose
NCT07087327
P3RecruitingAttention-Deficit Hyperactivity Disorder(ADHD)1802027-08
OPC-34712FUM/ Brexpiprazole fumarate
NCT05325645
P3RecruitingAcute Schizophrenia4502027-09 (+29 mo)
EB-1020 (Centanafadine) 164.4 mg
NCT06926829
P3RecruitingAttention Deficit Hyperactivity Disorder (ADHD)1802027-12
EB-1020 (Centanafadine) 164.4 mg
NCT06931080
P2/3RecruitingAttention Deficit Hyperactivity Disorder (ADHD)6302027-12
SEP-363856
NCT07225712
P3RecruitingSchizophrenia1002028-03